Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Oct 29;199(3):513–525. doi: 10.1083/jcb.201206143

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2012 Sumigray et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 2. — Cortical microtubules increase epidermal sheet integrity. (A) Epidermal sheet fragments resulting from mechanical disruption of untreated or taxol-treated keratinocytes. Bar, 1 cm. (B) Quantitation of sheet fragments resulting from mechanical disruption of keratinocyte monolayers. P = 0.0017 for control vs. taxol treatment; n = 5 for control, 7 for taxol treatment. (C) Quantitation of epidermal sheet stability in cells treated with normal rat serum (NRS) in the presence or absence of taxol and treated with the E-cadherin inhibitory antibodies, DECMA, in the presence or absence of taxol. P = 0.02. (D) Quantitation of epidermal sheet stability of α-catenin–null cells with and without taxol treatment. (E) Quantitation of epidermal sheet stability after treatment with the myosin II inhibitor (blebbistatin) with or without taxol (compare to control in B). (F) Epidermal sheet integrity in myosin IIA floxed cells, with or without Cre recombinase and taxol, as indicated. P < 0.0001. Error bars are SEM.